Abstract:Background:Hepatocellular carcinoma (HCC) is the most prevalent pathological type of liver cancer worldwide with high mortality and poor prognosis. N6-methyladenosine (m6A) can modify RNAs such as mRNA, lncRNA, miRNA, and tRNA, thereby playing a critical role in the pathogenesis of HCC. However, the role of m6A-associated small nuclear RNA (snRNA) in the prognostic value and immunotherapeutic response in HCC remains unclear.Materials and methods:In this study, snRNA expression data, gene mutation data, and clinical data of HCC patients were acquired from The Cancer Genome Atlas (TCGA) database. We used the least absolute shrinkage and selection operator (LASSO) Cox regression analysis to identify significant prognostic m6A-associated snRNAs, and then developed a multivariate Cox model based on the selected snRNAs. HCC patients were split into low- and high-risk groups based on the median risk score. We subsequently performed Kaplan-Meier curve analysis to estimate overall survival (OS) by clinicopathological characteristics and tumor mutational burden (TMB) status in low- and high-risk HCC patients. Finally, we compared the immunotherapeutic response as represented by tumor immune dysfunction and exclusion (TIDE) scores between the two risk groups.Results:Eight m6A-associated snRNAs were selected as independent predictors to develop the risk model. Our results revealed that the OS of HCC patients in the high-risk group was significantly worse than that in the low-risk group on clinicopathologic characteristics, including age (≤65 years and >65 years), gender (male), grade (G I-II and G III-IV) and TNM staging (Stage I-II and Stage III-IV). In addition, the OS of low-TMB and low-risk group was longer than that of high-TMB and high-risk group. The TIDE score indicated that HCC patients in the high-risk group were more susceptible to immunotherapy.Conclusion:Our study suggests that m6A-associated snRNAs may be useful biomarkers for the prognosis of HCC and that m6A-associated snRNA models can predict the effect of immunotherapy in HCC patients.

Targeting non-coding RNAs and N 6 -methyladenosine modification in hepatocellular carcinoma

Targeting Non-Coding RNAs and N6-methyladenosine Modification in Hepatocellular Carcinoma

New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Transcriptome Sequencing of Hepatocellular Carcinoma Uncovers Multiple Types of Dysregulated Ncrnas

Non-coding RNA Methylation Modifications in Hepatocellular Carcinoma: Interactions and Potential Implications

The role of RNA modifications in hepatocellular carcinoma: functional mechanism and potential applications

Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies

Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.

Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma

RNA m6A methylation regulators in liver cancer

A Double-Edged Sword: the HBV-induced Non-Coding RNAs Alterations in Hepatocellular Carcinoma

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Dysregulated N6-methyladenosine (m6A) processing in hepatocellular carcinoma

The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma

Mechanisms of RNA N 6 -Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology.

Implications of M6a-Associated Snrnas in the Prognosis and Immunotherapeutic Responses of Hepatocellular Carcinoma.

Roles of N6‐methyladenosine epitranscriptome in non‐alcoholic fatty liver disease and hepatocellular carcinoma

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer

The emerging roles of m6A modification in liver carcinogenesis